PLEASANTON, Calif., May 10 /PRNewswire-FirstCall/ -- Thoratec Corporation , a world leader in products to treat cardiovascular disease, said today it will be participating in the Bank of America Health Care Conference on Tuesday, May 16.
Gary F. Burbach, president and chief executive officer, will provide an update on the company, beginning at 5 p.m., Eastern Daylight Time (2 p.m., Pacific Daylight Time).
The presentation will be available through the conference web site at http://www.veracast.com/webcasts/bas/healthcare06/id29109279.cfm and also on the company’s web site, http://www.thoratec.com.
Thoratec Corporation is a world leader in hemodynamic restoration therapy-developing products to treat cardiovascular disease. The company’s product line includes the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 10,000 devices implanted in patients suffering from heart failure. Thoratec’s HeartMate LVAS is the first and, to date, only FDA-approved device for Destination Therapy, or the permanent support of advanced-stage heart failure patients who are not eligible for heart transplantation. Thoratec’s product line also includes the Vectra(R) vascular access graft (VAG) for patients undergoing hemodialysis. Additionally, its International Technidyne Corporation (ITC) division supplies point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web sites at http://www.thoratec.com or http://www.itcmed.com.
Thoratec Corporation
CONTACT: investors, Cynthia Lucchese, Senior Vice President, ChiefFinancial Officer of Thoratec Corporation, +1-925-847-8600; or Neal Rosenof Kalt Rosen & Company, +1-415-397-2686, for Thoratec; or Jennifer Volchokof FischerHealth, Inc., +1-310-577-7870, ext. 140, orjvolchok@fischerhealth.com, for Thoratec
Web site: http://www.thoratec.com//
